Oncolytics Biotech Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
ONCY•FDA feedback on pivotal REO 033 expansion
Oncolytics Biotech Inc. ONCY.O:
- Oncolytics Biotech aligns with the FDA on the registrational path for second-line Ras-mutant MSS colorectal cancer.
- Oncolytics Biotech receives FDA feedback on pivotal Part B expansion of REO 033.
Source text: ID:nGNX2J99Dk
Further company coverage: ONCY.O
Related News
Life Time Group Holdings, Inc <LTH.N>: Morgan Stanley raises target price to $53.00 from $39.00
LTH•
Galaxy Gaming completes GOS progressive blackjack jackpot rollout across MSC Cruises North America fleet
GLXZ•
